Innovative Lymphoma Research Advancing Cellular and Immunotherapies
Our researchers are at the forefront of new lymphoma research, developing new therapeutic platforms and cellular therapeutics to advance the treatment of lymphoma. We aim to not only develop new treatments but also improve and advance existing therapies to maximize their clinical benefit and progress from palliative to curative treatment.
Targeted Cell Therapy
Targeted agents are newer medications that selectively target lymphoma cells while causing minimal side effects to healthy organs. Lymphoma researchers at University Hospitals are collaborating with the pharmaceutical industry to identify drug targets and develop therapies that more precisely treat lymphomas and minimize side effects and potential complications by inhibiting disease pathways and cellular mechanisms.
CAR T-Cell and Immunotherapy
CAR T-cell therapy is a form of therapy in which the patient’s own immune system cells are harnessed and altered in a lab so that they attach to and kill lymphoma cells. UH Seidman Cancer Center is one of the few academic medical centers in the country to manufacture CAR T-cells and other cell-based immunotherapies on site.
Natural Killer (NK) Cells
A research team from UH Seidman Cancer Center and Case Western Reserve University School of Medicine is developing a next-generation cellular immunotherapy, BAFF CAR-NK cells, which early results suggest may be safer, more effective, and more accessible than existing therapies.
Bispecific T-cell engagers (BiTEs)
Researchers are investigating and developing the use of bispecific T-cell engagers, a type of immunotherapy that targets lymphoma cells by redirecting the body’s immune cells to attack and kill cancer cells.
Bruton’s Tyrosine Kinase (BTK) Degraders
Lymphoma researchers at University Hospitals are studying a novel class of drugs called BTK degraders, which target and destroy Bruton tyrosine kinase, a protein that is critical in the development and progression of certain types of lymphoma.
Developing Clinical Pathways
Clinicians and researchers at University Hospitals are developing improved clinical pathways to guide effective lymphoma treatment while balancing efficacy and side effects.